Eupraxia Pharmaceuticals has priced a public offering of common shares and pre-funded warrants totaling $55 million, with common shares set at $7.00 per share and pre-funded warrants priced at $6.99999 per warrant. The capital raise is expected to close on February 20, 2026.
The biopharmaceutical company intends to allocate the proceeds primarily toward advancing EP-104GI, its lead candidate for eosinophilic esophagitis, through Phase 2 clinical development and Phase 3 preparation activities. Beyond its flagship program, Eupraxia plans to leverage the funding to explore additional therapeutic applications within the gastrointestinal disease space, broadening its clinical development portfolio.
This offering provides the company with capital to progress its clinical pipeline as it seeks to address treatment gaps in gastrointestinal disorders. The timing of the offering and anticipated closing date position Eupraxia to accelerate development timelines for its lead program while evaluating expansion opportunities in related indications.